Pasithea Therapeutics files Alpha-5 Integrin financials for acquisition closed June 21, 2022

Pasithea Therapeutics Corp.

Alpha-5 (preclinical-stage, ALS/neuroinflammatory mAbs) had no revenue and $1.7M net loss for FY 2021.
Q1 2022 net loss was $447k; accumulated deficit reached $2.15M as of March 31, 2022.
Total assets $200k, cash & equivalents $122k at March 31, 2022, down from $295k at year-end 2021.
Acquisition closed June 21, 2022; one seller is Pasithea's Executive Chairman and Co-Founder.
Pro forma adjustments deemed immaterial; Alpha-5 became a wholly owned subsidiary of Pasithea.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.